HHS Public Access Author manuscript Author Manuscript

Early Hum Dev. Author manuscript; available in PMC 2016 December 01. Published in final edited form as: Early Hum Dev. 2015 December ; 91(12): 725–729. doi:10.1016/j.earlhumdev.2015.08.003.

Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus Brian C. Gulack, MDa, Matthew M. Laughon, MD, MPHb, Reese H. Clark, MDc, Meera N. Sankar, MDd, Christoph P. Hornik, MD, MPHe,f, and P. Brian Smith, MD, MPH, MHSe,f

Author Manuscript

aDepartment

of Surgery, Duke University School of Medicine, Durham, NC, United States

bDepartment

of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United

States cPediatrix

Medical Group, Inc., Sunrise, FL, United States

dPediatrix

Medical Group, San Jose, CA, United States

eDepartment

of Pediatrics, Duke University School of Medicine, Durham, NC, United States

fDuke

Clinical Research Institute, Duke University School of Medicine, Durham, NC, United States

Abstract Author Manuscript

Background—Patent ductus arteriosus (PDA) is common in extremely premature infants and associated with increased morbidity and mortality. Medical management of PDA uses either indomethacin or ibuprofen. Despite numerous studies, uncertainty exists as to which drug is safer or more effective; we sought to fill this knowledge gap. Methods—We identified infants